{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:09:11Z","timestamp":1792638551840,"version":"4.5.0"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Osimertinib is a first-line (1L) treatment option for patients with locally advanced\/metastatic epidermal growth factor receptor (\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      )-mutated non-small-cell lung cancer (NSCLC). Resistance to 1L osimertinib often develops and treatment options after disease progression are limited. The clinical benefit of 1L osimertinib in combination with agents which have broad antitumor activity has been demonstrated in phase III trials. Datopotamab deruxtecan (Dato-DXd), an antibody\u2013drug conjugate composed of a humanized anti-trophoblast cell-surface antigen 2 monoclonal antibody conjugated to a potent topoisomerase I inhibitor, has demonstrated efficacy as monotherapy and in combination with osimertinib in NSCLC, including patients with\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      -mutated advanced NSCLC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>\n                      TROPION-Lung14 (NCT06350097), an ongoing phase III, open-label, sponsor-blind, multicenter, randomized study, is evaluating the efficacy and safety of osimertinib\u2009+\u2009Dato-DXd, versus osimertinib, as 1L therapy in patients with\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      -mutated LA\/M NSCLC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and design:<\/jats:title>\n                    <jats:p>\n                      The study is enrolling adults with histologically\/cytologically confirmed stage IIIB\/IIIC or intravenously (IV) non-squamous,\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      -mutated (exon 19 deletion (Ex19del) or L858R) NSCLC, and no prior EGFR-TKI or other systemic therapy for stage IIIB\/IIIC or IV disease. Prior to the randomized study period, ~20 patients will receive osimertinib\u2009+\u2009Dato-DXd in a safety run-in. Following safety run-in, ~562 patients will be randomized 1:1 to osimertinib (80\u2009mg orally once daily (PO QD))\u2009+\u2009Dato-DXd (6\u2009mg\/kg IV every 3\u2009weeks) or osimertinib (80\u2009mg PO QD). Patients will be stratified by\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      mutation type (Ex19del vs L858R), World Health Organization performance status (0 vs 1), and central nervous system metastasis (yes vs no). Treatment will continue until Resist Evaluation Criteria in Solid Tumors version 1.1-defined progression or unacceptable toxicity. The primary endpoint is progression-free survival by blinded independent central review. Overall survival is a key secondary endpoint.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics:<\/jats:title>\n                    <jats:p>The study is approved by independent ethics committees\/institutional review boards at each center. Patients will provide informed consent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>\n                      TROPION-Lung14 will assess 1L osimertinib\u2009+\u2009Dato-DXd versus osimertinib alone in patients with\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      -mutated LA\/M NSCLC, potentially providing a new treatment option.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifier: NCT06350097 (Registration Date: April 5, 2024).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261430561","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:24:29Z","timestamp":1779272669000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with\n                    <i>EGFR<\/i>\n                    -mutated locally advanced or metastatic non-small cell lung cancer"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-7262","authenticated-orcid":false,"given":"Shun","family":"Lu","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Shanghai Chest Hospital, Shanghai 200030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano Provencio","family":"Pulla","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldsamira","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Hospital Sao Rafael, Salvador, Brazil"},{"name":"Instituto D\u2019Or de Pesquisa e Ensino (IDOR), Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tanizaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1842-9070","authenticated-orcid":false,"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglei","family":"Liu","sequence":"additional","affiliation":[{"name":"AstraZeneca, R&amp;D, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengmei","family":"Feng","sequence":"additional","affiliation":[{"name":"AstraZeneca, R&amp;D, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Zhang","sequence":"additional","affiliation":[{"name":"AstraZeneca, R&amp;D, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Toms","sequence":"additional","affiliation":[{"name":"AstraZeneca, R&amp;D, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Chih-Hsin","family":"Yang","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, National Taiwan University Hospital, Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0337"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1994"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030841"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01626"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.015"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0206"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01544"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01349"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00059"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.06.002"},{"key":"e_1_3_5_19_2","unstructured":"US Food and Drug Administration (FDA). DATROWAY\u00ae (datopotamab deruxtecan-dlnk) for injection for intravenous use. Initial U.S. Approval 2025. Highlights of prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761464s000lbl.pdf (2025 accessed 19 November 2025)."},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-LB458"},{"key":"e_1_3_5_21_2","volume-title":"Osimertinib\u2009+\u2009datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC whose disease progressed on first-line osimertinib: ORCHARD","author":"Le X","unstructured":"Le X, Hendriks L, Morabito A, et al. Osimertinib\u2009+\u2009datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC whose disease progressed on first-line osimertinib: ORCHARD. Oral presentation 10 at the European Lung Cancer Congress (ELCC), 26\u201329 March 2025, Paris, France."},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9004"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104164"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081477"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388"},{"key":"e_1_3_5_26_2","article-title":"TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib","author":"Tan DS","unstructured":"Tan DS, Nadal E, Cheema P, et al. TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib. Ther Adv Med Oncol 2025; 17.","journal-title":"Ther Adv Med Oncol"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261430561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261430561","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261430561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:16:16Z","timestamp":1779452176000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261430561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"alternative-id":["10.1177\/17588359261430561"],"URL":"https:\/\/doi.org\/10.1177\/17588359261430561","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"17588359261430561"}}